Evidence map›Paper›PMID 41677949›Full record

ArticleCancer immunology, immunotherapy : CII2026

TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms.

Qikai Zhou, Zhixue Wang, Yixian Cao, Zhengheng Zheng, Wen Li, Zifeng Fu, Wenqin Luo, Wei-Qiang Gao, Bin Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qikai Zhou *School of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China.
Zhixue Wang *School of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China.
Yixian CaoSchool of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China.
Zhengheng ZhengSchool of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China.
Wen LiSchool of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China.
Zifeng FuSchool of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China.
Wenqin LuoDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Wei-Qiang GaoSchool of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China.
Bin MaShanghai Key Laboratory for Cancer System Regulation and Clinical Translation, Shanghai Jiading District Central Hospital, Shanghai, China. bin.ma@outlook.com.ORCID http://orcid.org/0000-0001-5744-9667

Funding

Ministry of Science and Technology of the People's Republic of China 2023YFC3404101National 111 Project of China B21024National Natural Science Foundation of China W2431055Natural Science Foundation of Chongqing Municipality CSTB2024NSCQ-KJFZMSX0044Science and Technology Commission of Shanghai Municipality 25ZR1401313Shanghai Jiading District Health Commission 2025-KY-ZD-05
6 · The paper itself

Abstract

Pattern recognition receptors (PRRs) are crucial modulators of the tumor immune microenvironment (TIME); yet, their comparative efficacy remains poorly characterized. Platelet factor 4 (PF4/CXCL4) exerts paradoxical effects in cancer, and its regulation by PRR signaling is unclear. Here, we systematically screened PRR agonists in murine tumor models and identified TLR8 agonists as the most potent inducers of a pro-immunogenic TIME, superior to agonists targeting TLR3/7/9 or NOD1/2. TLR8 activation drove CD45

Indexed as

Platelet Factor 4Toll-Like Receptor 8Tumor MicroenvironmentAnimalsCell Line, TumorHumansMacrophagesMiceMice, Inbred C57BLToll-Like Receptor AgonistsPlatelet Factor 4Toll-Like Receptor 8Toll-Like Receptor AgonistsCXCL4ImmunotherapyPF4PRRTLR8Tumor immune microenvironment

Identifiers

PMID41677949
PMCPMC12901762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.